Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
Total Valuation
Neurosense Therapeutics Ltd. has a market cap or net worth of $22.63M. The enterprise value is $18.80M.
Market Cap$22.63M
Enterprise Value$18.80M
Share Statistics
Neurosense Therapeutics Ltd. has 29,699,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,699,320
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Neurosense Therapeutics Ltd.’s return on equity (ROE) is 7.13 and return on invested capital (ROIC) is 797.48%.
Return on Equity (ROE)7.13
Return on Assets (ROA)-10.82
Return on Invested Capital (ROIC)797.48%
Return on Capital Employed (ROCE)7.45
Revenue Per Employee0.00
Profits Per Employee-654.41K
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neurosense Therapeutics Ltd. is ―. Neurosense Therapeutics Ltd.’s PEG ratio is 0.09.
PE Ratio―
PS Ratio0.00
PB Ratio-12.56
Price to Fair Value-12.56
Price to FCF-2.55
Price to Operating Cash Flow-9.68K
PEG Ratio0.09
Income Statement
In the last 12 months, Neurosense Therapeutics Ltd. had revenue of 0.00 and earned -11.13M in profits. Earnings per share was -0.44.
Revenue0.00
Gross Profit0.00
Operating Income-11.09M
Pretax Income-11.13M
Net Income-11.13M
EBITDA-11.07M
Earnings Per Share (EPS)-0.44
Cash Flow
In the last 12 months, operating cash flow was -2.00K and capital expenditures 0.00, giving a free cash flow of -2.00K billion.
Operating Cash Flow-2.00K
Free Cash Flow-2.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Neurosense Therapeutics Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.22
52-Week Price Change-19.54%
50-Day Moving Average0.87
200-Day Moving Average1.18
Relative Strength Index (RSI)44.11
Average Volume (3m)944.42K
Important Dates
Neurosense Therapeutics Ltd. upcoming earnings date is Sep 2, 2026, Before Open (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateSep 2, 2026
Ex-Dividend Date―
Financial Position
Neurosense Therapeutics Ltd. as a current ratio of 0.31, with Debt / Equity ratio of -10.90%
Current Ratio0.31
Quick Ratio0.31
Debt to Market Cap0.00
Net Debt to EBITDA>-0.01
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neurosense Therapeutics Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Neurosense Therapeutics Ltd. EV to EBITDA ratio is -1.77, with an EV/FCF ratio of -2.55.
EV to Sales0.00
EV to EBITDA-1.77
EV to Free Cash Flow-2.55
EV to Operating Cash Flow-2.55
Balance Sheet
Neurosense Therapeutics Ltd. has $666.00K in cash and marketable securities with $0.00 in debt, giving a net cash position of $666.00K billion.
Cash & Marketable Securities$666.00K
Total Debt$0.00
Net Cash$666.00K
Net Cash Per Share$0.02
Tangible Book Value Per Share-$0.06
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Neurosense Therapeutics Ltd. is $6.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.50
Price Target Upside755.26% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast31.09%